DMTx

Noonautics in partnership with Eleusis founded a government-licensed research institute and retreat center in the Caribbean, dedicated to consciousness research with a particular focus on extended-state DMT (DMTx) investigations. Our mission integrates rigorous intravenous infusion science with real-time participant control, in a protected, medically supervised tropical environment. By applying target-controlled infusion technology—originally invented by Noonautics director Dr. Andrew Gallimore and now incorporating the Basel “self-titration” paradigm—we enable explorers to navigate and map DMT’s visionary realms continuously, much like NASA/SETI missions chart uncharted frontiers. Simultaneously, we are focused on developing novel mental-health therapeutic protocols using this technology that adapt dynamically to each individual’s needs.

Real-Time Self-Titration Technology

Building on the principle that participants can safely steer their DMT experience, we will employ programmable infusion pumps linked to a simple user interface. At predefined intervals, volunteers indicate “increase,” “decrease,” or “hold” their dose, and clinicians adjust infusion rates accordingly:

• Unlimited Duration.  Unlike the 120-minute ceiling of earlier trials, our protocols allow sessions of several hours or more, facilitating prolonged exploratory “missions.”

• Dose Modulation.  Drawing from pharmacokinetic models, infusion rates can range flexibly and be altered on demand, yielding a stable plateau of intensity.

• Safety Mechanisms.  Continuous vital-sign monitoring, acute tolerance buffering, and an immediate “off switch” ensure tolerability throughout extended exposures.

Mystical and Worldview Transformations

Large-scale surveys reveal profound belief shifts following DMT journeys:

• Johns Hopkins Survey: Over two-thirds of self-identified atheists abandoned atheism after a “God” or “ultimate reality” encounter—606 respondents reported using DMT in these experiences  .

• Psychedelic User Analysis: Mystical DMT sessions reduced self-reported atheism from 25% to 7%, underscoring DMT’s capacity to induce enduring ontological shifts  .

Noonautics will systematically document such encounters, leveraging extended exposure to study the phenomenology of non-human intelligences, interpersonal “shared realities,” and the cognitive mechanisms underlying lasting belief change.

Therapeutic Potential of DMTx

Emerging clinical evidence positions DMT as a rapid-acting intervention for treatment-resistant conditions:

• Phase 2a TRD Trial (Nature Neuropsychopharmacology 2025): Vaporized DMT produced 85.7% response and 57.1% remission at day 7, with benefits persisting up to 3 months after a single session  .

• Exploratory IV Study (D’Souza et al., 2022): Single IV boluses demonstrated dose-related safety, tolerability, and acute mood enhancement in healthy and depressed volunteers, supporting infusion-based delivery.

• Broader Psychedelic Literature: Reviews highlight DMT’s promise in neuroplasticity and emotion regulation, similar to psilocybin and ayahuasca interventions (Vollenweider & Preller 2020; Carhart-Harris et al. 2021).

Noonautics’ extended-state approach aims to optimize therapeutic windows, allowing clinicians to deepen or soften the psychedelic state in real time—potentially improving safety, integration, and long-term outcomes beyond single-bolus models.

Research Agenda

1. Phenomenological Mapping: Employ EEG, fMRI, and interactive logs during multi-hour DMTx missions to correlate neural signatures with subjective reports of entity contact and spatial navigation.

2. Adaptive Psychotherapy Protocols: Develop DMTx-guided therapy frameworks where dose modulation synchronizes with therapeutic phases—intensive exploration, integrative dialogue, and calibration.

3. Longitudinal Outcomes: Track mental-health metrics (depression, PTSD, substance use, etc.) over 6–12 months post-DMTx, comparing fixed-dose and self-titration paradigms.

4. Technology Innovation: Pilot infusion interfaces with biofeedback loops (e.g., heart-rate variability) to enable semi-autonomous dose adjustments under supervision.

Conclusion

Noonautics stands at the vanguard of a new era in psychedelic science—extending DMT’s brief spark into sustained voyages of consciousness, with participants captains of their own journeys. By marrying NASA/SETI-style exploration with precision mental-health therapeutics, we aspire to unlock realms of insight, foster transformative healing, and chart the uncharted territories of the mind.